Advertisement

Substanzgruppen

  • Margot Schmitz

Zusammenfassung

Bei Untersuchungen von Strukturvarianten bekannter Neuroleptika wurden vor über 60 Jahren die antidepressiven Wirkungen von Imipramin entdeckt. Mit der überzeugenden Wirksamkeit des Imipramin und seinen Analogenden trizyklischen Antidepressiva — wurde eine neue Ära in der medikamentösen Behandlung der Depression eingeläutet. Alle trizyklischen Antidepressiva hemmen die Wiederaufnahme von Neurotransmittern, insbesondere von den biogenen Aminen Serotonin, Noradrenalin und Dopamin. Ihre anticholinerge Wirkung ist therapeutisch unerwünscht und verursacht typische Nebenwirkungen wie Mundtrockenheit, verschwommenes Sehen und Harnverhalten. Bald danach wurden die Monoaminoxidase-Inhibitoren entdeckt, die durch Hemmung des Abbauenzyms der biogenen Amine eine vergleichbare Wirkung erzielten. Die zufällige Beobachtung der stimmungsaufhellenden Wirkung des Tuberkulosemedikaments Iproniazid in den frühen 50er Jahren und die Bestätigung der Wirkung bei depressiven Patienten führte zu der Erkenntnis, dass eine Nebenwirkung — die Hemmung der Monoaminoxidase — ein neues Prinzip zur Behandlung der Depression darstelle. Diese beiden Substanzklassen bildeten über viele Jahre die Standardtherapie der Depression. Hauptproblem sind die zum Teil schweren kardiotoxischen Nebenwirkungen, wobei etwa nach Suizidversuchen die Herzrhythmusstörungen schwer in den Griff zu bekommen sind.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Abschnitt 4.1

  1. Akiskal HS (1994) Dysthymic and cyclothymic depressions: therapeutic considerations. J Clin Psychiatry 55(Suppl 4):46–52PubMedGoogle Scholar
  2. Akiskal HS, Cassano GB (eds) (1997) Dysthymia and the spectrum of chronic depressions. Guilford Press, New YorkGoogle Scholar
  3. American Psychiatric Association (2000) Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157(Suppl 4):l–45Google Scholar
  4. Angst J, Sellaro R, Merikangas KR (2000) Depressive spectrum diagnoses. Compr Psychiatry 41(Suppl l):39–47PubMedCrossRefGoogle Scholar
  5. Armitage R, Yorkers K, Cole D et al (1997) A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17:161–168PubMedCrossRefGoogle Scholar
  6. Appels AD (2002) Depression and cardiac disease. Curr Opin Psych 15(l):59–62CrossRefGoogle Scholar
  7. Baldassano CF, Sachs GS, Stoll AL et al (1995) Paroxetine for bipolar depression: outcome in patients failing prior antidepressant trials. Depression 3:182–186CrossRefGoogle Scholar
  8. Ballenger JC, Wheadon DE, Steiner M et al (1998) Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155(l):36–42PubMedGoogle Scholar
  9. Ban TA, Gszner P et al (1998) Clinical Efficacy of Reboxetine: a Comparative Study with Desipramine, with Methodological Considerations. Human Psychopharmacol 13:29–39CrossRefGoogle Scholar
  10. Bauer M (1995) The combined use of lithium and SSRIs. J of Serotonin Research 2:69–76Google Scholar
  11. Bauer M et al (2002) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 3(2):69–86PubMedCrossRefGoogle Scholar
  12. Baumann P, Nil R, Bertschy G et al (1998) A double-blind double-dummy study of citalopram comparing infusion versus oral administration. J Affective Disorders 49:203–210CrossRefGoogle Scholar
  13. Benkert O, Szegedi A, Wetzel H et al (1997) Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 95:288–296PubMedCrossRefGoogle Scholar
  14. Berzewski H, Van Moffaert M, Gagiano C (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients from major depressive episodes. European Neuropsychopharmacol 7(suppl):1:37–47CrossRefGoogle Scholar
  15. Bodkin JA, Amsterdam JD (2002) Transdermal Selegiline in Major Depression: A Double Blind, Placebo-Controlled, Parallel-Group Study in Outpatients. Am J Psychiatry 159:1869–1875PubMedCrossRefGoogle Scholar
  16. Bouwer C, Stein DJ (1998) Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affective Disorders 49: 79–82CrossRefGoogle Scholar
  17. Bowden CL (1998) Key treatment studies of lithium in manic-depressive illness: Efficacy and side effects. J Clin Psychiatry 59(suppl 6):13–19PubMedGoogle Scholar
  18. Bowden CL, Calabrese JR, McElroy SL (2000) A randomized, placebo controlled 12 month trial of divalproat and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 57:481–489PubMedCrossRefGoogle Scholar
  19. Brambilla P, Barale F, Soares JC (2001) Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int J Neuropsychopharm 4:421–446Google Scholar
  20. Burnett FE, Dinan TG (1998) The clinical efficacy of venlafaxine in the treatment of depression. Rev Contemp Pharmacother 9:303–320Google Scholar
  21. Calabrese J (2000) A double-blind, placebo controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 61:841–850PubMedCrossRefGoogle Scholar
  22. Calabrese J (2000) A double blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60:79–88CrossRefGoogle Scholar
  23. Carpenter L, Yasmin S, Price LH (2002) Eine doppelblinde Placebo-kontrollierte Studie über die Augmentation von Antidpressiva mit Mirtazapin. Biol Psychiatry 51:183–188PubMedCrossRefGoogle Scholar
  24. Chengappa KNR, Gershon S, Levine J (2001) The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disorders 3:215–232PubMedCrossRefGoogle Scholar
  25. Citrome L (2002) Current Treatments of Agitation and Aggression. http://www.medscape.com/viewprogram/1866_pnt
  26. Coppen A (2000) Lithium in unipolar depression and the prevention of suicide. J Clin Psychiatry 61(Suppl 9):52–56PubMedGoogle Scholar
  27. Davis JM et al (1999) Mood stabilizers in the prevention of recurrent affective disorders: a meta analysis. Acta Psychiatr Scand 100:406–417PubMedCrossRefGoogle Scholar
  28. De Jonghe F, Kool S, van Aalst G, Dekker J, Peen J (2001) Combining psychotherapy and antidepressants in the treatment of depression. J of Affective Disorder 64:217–229CrossRefGoogle Scholar
  29. Dierick M, Martin A, Ravizza L et al (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry Jan 20(l):57–71CrossRefGoogle Scholar
  30. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Brit J Psychiatry 160:217–222CrossRefGoogle Scholar
  31. Dubini A, Bosc M, Polin V (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 11(suppl 4):17–23Google Scholar
  32. Dunner DL (1998) Lithium carbonate: Maintenance studies and consequencies of withdrawal. J Clin Psychiatry 59(suppl 6):48–55PubMedGoogle Scholar
  33. Elliott AJ, Uldall KK, Bergam K et al (1998) Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatr 155(3):367–372PubMedGoogle Scholar
  34. Fabre FL et al (1995) Sertraline safety and efficacy in major depression: a doubleblind fixed-dose comparison with placebo. Biol Psychiatry 38:592–602PubMedCrossRefGoogle Scholar
  35. Fava M, Rosenbaum J, Hoog S et al (1998) Fluoxetine versus sertraline and paroxetine in major depression: long term changes in weight. European Neuropsychopharmacol 8(suppl 2):204CrossRefGoogle Scholar
  36. Fava GA et al (1998) Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 55:816–820PubMedCrossRefGoogle Scholar
  37. Feiger A, Kiev A, Shrivastava R et al (1996) Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57(suppl 2):53–62PubMedGoogle Scholar
  38. Flament MF, Bisserbe JC (1997) Pharmacologic treatment of OCD: comparative studies. J Clin Psychiatr 58(suppl 12):18–22Google Scholar
  39. Frampton M (1997) Citalopram: a review of pharmacology and clinical efficacy. J Serotonin Research 4:29–45Google Scholar
  40. Franchini L et al (1997) A double blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 58:104–197PubMedCrossRefGoogle Scholar
  41. Franchini L, Gasperini M, Perez J et al (1998) Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 59(5):229–232PubMedCrossRefGoogle Scholar
  42. Geretsegger C, Stuppaeck CH, Mair M et al (1995) Multicenter double blind study of paroxetine and amitryptiline in elderly depressed patients. Psychopharmacol 119:277–281CrossRefGoogle Scholar
  43. Ghose K (1997) Tolerance and side-effects of paroxetine in elderly depressed patients. Archives of Gerontol Geriatrics 24:35–45CrossRefGoogle Scholar
  44. Gorman JM, Korotzer A, Su G (2002) Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials. Med Works Media 40–44Google Scholar
  45. Gottfries CG (1996) Scandinavian experience with citalopram in the elderly. International Clinical Psychopharmacology 11(suppl l):41–44PubMedCrossRefGoogle Scholar
  46. Heal D, Cheetham S et al (1992) Comparative Pharmacology of Dothiepin, its Metabolites, and Other Antidepressant Drugs. Drug Development Res 27:121–135CrossRefGoogle Scholar
  47. Healy D, McMonagle T (1997) The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol 11(suppl 4):25–31Google Scholar
  48. Hindmarch I (1997) The effects of antidepressants on psychomotor function with particular reference to reboxetine. European Neuropsychopharmacol 7(suppl 1):17–21Google Scholar
  49. Hindmarch I (1998) Effect of Antidepressants on Cognitive and Psychomotor Function: the Lack of Effect of Reboxetine. Human Psychopharmacol 13:21–27CrossRefGoogle Scholar
  50. Judd LL (1997) The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 54:989–991PubMedCrossRefGoogle Scholar
  51. Judd LL, Akiskal HS (2000) Delineating the longitudinal structure of depressive illness: beyond subtypes and duration thresholds. Pharmacopsychiatry 33:3–7PubMedCrossRefGoogle Scholar
  52. Judd LL et al (2000) Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 157:1501–1504PubMedCrossRefGoogle Scholar
  53. Katona CLE, Hunter BN, Bray J (1998) A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatric Psychiatry 13:100–108CrossRefGoogle Scholar
  54. Katzelnik DJ et al (1995) Sertraline for social phobia: a double-blind, placebo controlled crossover study. Am J Psychiatry 152:1368–1371Google Scholar
  55. Keller MB, Kocsis JH, Thase ME et al (1998) Maintenance phase efficacy of sertraline for chronic depression. JAMA 280(19):1665–1671PubMedCrossRefGoogle Scholar
  56. Keller MB et al (2000) A comparison of nefazodone, the cognitive behavioralanaly-sis system of psychotherapy and their combination for the treatment of chronic depression. N Engl J Med342:1462–1470PubMedCrossRefGoogle Scholar
  57. Kerr JS, Hindmarch I (1996) Citalopram and other antidepressants: comparative effects on cognitive function and psychomotor performance. J Serotonin Res 3:123–129Google Scholar
  58. Kerr JS, Fairweather DB, Hindmarch I (1997) The effect of paroxetine and dothiepin on subjective sleep in depressed patients. Human Psychopharmacol12:71–73CrossRefGoogle Scholar
  59. Kessler RC et al (1994) Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51:8–19PubMedCrossRefGoogle Scholar
  60. Klein DN et al (1988) Double depression and episodic major depression: demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome. Am J Psychiatry 145:1226–1231PubMedGoogle Scholar
  61. Klerman GL, Weissman MM (1989) Increasing rates of depression. JAMA 261:2229–2235PubMedCrossRefGoogle Scholar
  62. Kocsis JH, Friedman RA, Markovitz JC et al (1996) Maintenance therapy for chronic depression. A controlled clinical trial of desipramine. Arch Gen Psychiatry 53:769–774PubMedCrossRefGoogle Scholar
  63. Kocsis JH, Zisook S, Davidson J et al (1997) Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 154:390–395PubMedGoogle Scholar
  64. Kupfer DJ (1993) Management of recurrent depression. J Clin Psychiatry 54 (Suppl 2):29–33PubMedGoogle Scholar
  65. Lader M (1996) Citalopram — a new antidepressant. Primary Care Psychiatry 2:49–58Google Scholar
  66. Lane R, Baldwin D, Preskorn S (1995) The SSRIs: advantages, disadvantages and differences. J Psychopharmacol 9(Suppl 2):163–178PubMedGoogle Scholar
  67. Lecrubier Y (1995) Clinical utility of venlafaxine in comparison with other antidepressants. Int Clin Psychopharmacol 10(suppl 2):29–35PubMedCrossRefGoogle Scholar
  68. Lecrubier Y, Bakkier A, Dumbar G et al (1997) A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 95:145–152PubMedCrossRefGoogle Scholar
  69. Lecrubier Y, Judge R et al (1997) Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 95:153–160PubMedCrossRefGoogle Scholar
  70. Lepola UM, Wade AG, Leinonen EV et al (1998) A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59(10):528–534PubMedCrossRefGoogle Scholar
  71. Lima MS, Moncrieff J (2001) Drugs versus placebo for dysthymia (Cochrane Review). In: The Cochrance Library, Issue 1, 2001 Update Software, OxfordGoogle Scholar
  72. Londborg PD, Wolow R, Smith WT et al (1998) Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Brit J Psychiatry 173:54–60CrossRefGoogle Scholar
  73. Marshall RD, Schneier FR, Fallon BA et al (1998) An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 18(l):10–18PubMedCrossRefGoogle Scholar
  74. Massana J (1998) Reboxetine Versus Fluoxetine: an Overview of Efficacy and Tolerability. J Clin Psychiatry 59(suppl)Google Scholar
  75. McElroy SL, Arnold LM, Shapira NA et al (2003) Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A randomized, placebo-controlled trial. Am J Psychiatry 160(2):255–261PubMedCrossRefGoogle Scholar
  76. Mendels J, Kiev A, Fabre LF (1999) Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depression and Anxiety 9:54–60PubMedCrossRefGoogle Scholar
  77. Menza MA, Kaufman KR, Castellanos AM (2000) Modafinil Augmentation of Antidepressant Treatment in Depression. J Clin Psychiatry 378–381Google Scholar
  78. Miller NL et al (2001) Maintenance desipramine for dysthymia: a placebo controlled study. J Affect Disord 64:231–237PubMedCrossRefGoogle Scholar
  79. Montgomery SA (1997) Reboxetine: additional benefits to the depressed patient. J Psychopharmacol ll(suppl 4):9–15Google Scholar
  80. Montgomery SA (1999) New developments in the treatment of depression. J Clin Psychiatry 60(Suppl 14):10–15PubMedGoogle Scholar
  81. Montgomery SA, Djärv L (1996) The antidepressant efficacy of citalopram. Intern Clin Psychopharmacol ll(suppl l):29–33CrossRefGoogle Scholar
  82. Moscovich DG, Shapira B et al (1992) Rapid Lithiumization in Acute Manic Patients. Human Psychopharm 7:343–345CrossRefGoogle Scholar
  83. Mucci M (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 11(suppl 4):33–37Google Scholar
  84. Müller-Öhrlinghausen B et al (1999) Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 156:1000–1006Google Scholar
  85. Nemeroff CB (2000) An ever increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 61(suppl 13):19–25PubMedGoogle Scholar
  86. Newhouse PA (1996) Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 57(suppl 5):12–22PubMedGoogle Scholar
  87. Nolen WA, Bloemkolk D (2000) Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm. Neuropsychobiology 42(suppl 1): 11–17PubMedCrossRefGoogle Scholar
  88. Nierenberg AA (2001) Long-term management of chronic depression. J Clin Psychiatry 62(Suppl 6):17–21Google Scholar
  89. Nulman I, Rovet J et al (1997) Neurodevelopment of Children exposed in Utero to Antidepressant Drugs. New England J Medicine 336(4):258–262CrossRefGoogle Scholar
  90. Ontiveros A, Garcia-Barriga C (1997) A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Brit J Clinical Research 8:23–32Google Scholar
  91. Peet M, Pratt P (1993) Lithium: Current Status in Psychiatric Disorders. Drugs 46:7–17PubMedCrossRefGoogle Scholar
  92. Pohl RB, Wolkow RM, Clary C (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155(9):1189–1195PubMedGoogle Scholar
  93. Pollack MH, Otto MW, Worthington JJ et al (1998) Sertraline in the treatment of panic disorder. A flexible-dose multicenter trial. Arch Gen Psychiatry 55(ll):1010–1016PubMedCrossRefGoogle Scholar
  94. Potter WZ, Rudorfer MV, Manji H (1991) The pharmacologic treatment of depression. New England J Medicine 325(9):633–642CrossRefGoogle Scholar
  95. Ravidran AV, Judge R, Hunter BN et al (1997) A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatry 58(3):112–118CrossRefGoogle Scholar
  96. Rocca P, Fonzo V, Scotta Met al (1997) Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95:444–450PubMedCrossRefGoogle Scholar
  97. Rush AJ, Thase ME (1997) Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 58(Suppl 13):14–22PubMedGoogle Scholar
  98. Salokangas RKR, Saarijärvi S, Taiminen T et al (1996) Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 94:175–180PubMedCrossRefGoogle Scholar
  99. Schou M (1997) Lithiumbehandlung der manisch-depressiven Krankheit. Thieme, Stuttgart (4. Aufl.)Google Scholar
  100. Schou M (2000) Suicidal behavior and prophylactic lithium treatment of major mood disorders: a review of reviews. Suicide Life Threat Behav 30:289–293PubMedGoogle Scholar
  101. Scott J (1988) Chronic depression. Br J Psychiatry 153:287–297PubMedCrossRefGoogle Scholar
  102. Shekelle PG et al (1999) Clinical guidelines: developing guidelines. BMJ 318: 593–596PubMedCrossRefGoogle Scholar
  103. Simon GE (2002) Implementing depression treatment guidelines. Curr Opin Psych 15(l):77–82CrossRefGoogle Scholar
  104. Sinclair J, Birtwistle J, Baldwin D (1998) The tolerability of venlafaxine. Rev Contemp Pharmacother 9:333–344Google Scholar
  105. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Brit J Psychiatry 180:396–404CrossRefGoogle Scholar
  106. Stein DJ, Bouwer C, Maud CM (1997) Use of selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania. Eur Arch Psychiatry Clin Neurosci 247:234–236PubMedCrossRefGoogle Scholar
  107. Stein MB, Liebowitz MR, Lydiard B et al (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder). A randomized controlled trial. JAMA 280(8):708–713Google Scholar
  108. Sundblad C, Wikander I, Andersch B et al (1997) A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur Neuropsychopharmacol 7:201–206PubMedCrossRefGoogle Scholar
  109. Taiminen TJ, Syvällahti E, Saarijärvi S et al (1997) Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Intern Clin Psychopharmacol 12:31–35CrossRefGoogle Scholar
  110. Thase ME (1999) Long-term nature of depression. J Clin Psychiatry 60(Suppl 14): 3–9Google Scholar
  111. Thase ME, Faca M, Halbreich U et al (1996) A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53:777–784PubMedCrossRefGoogle Scholar
  112. Thase ME, Greenhouse JB, Frank E, Reynolds CF, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ (1997) Treatment of Major Depression with psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 54:1009–1015PubMedCrossRefGoogle Scholar
  113. Thase ME, Entsuah RA, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Brit J Psychiatry 178:234–241CrossRefGoogle Scholar
  114. Thies-Flechtner K et al (1996) Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomised prospective trial. Pharmacopsychiatry 29:103–107PubMedCrossRefGoogle Scholar
  115. Tiihonen J, Ryynänen OP, Kauhanen J et al (1996) Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiat 29:27–29CrossRefGoogle Scholar
  116. Tome MB, Isaac MT, Harte Ret al (1997) Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 12:81–89PubMedCrossRefGoogle Scholar
  117. Tondo L, Ross MD, Baldessarini RJ et al (1998) Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 155(5):638–645PubMedGoogle Scholar
  118. Tondo L, Baldessarini RJ, Floris (2001) Long term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 178(suppl 41):184–190CrossRefGoogle Scholar
  119. Tueth MJ, Murphy TK, Evans DL (1998) Special considerations: use of lithium in children, adolescents, and elderly populations. J Clin Psychiatry 59(suppl 6): 66–73Google Scholar
  120. Van Moffaert et al (1995) A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Human Psychopharmacol 10:393–405CrossRefGoogle Scholar
  121. Verkes RJ, Van der Mast RC, Hengeveld MW et al (1998) Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 155(4):543-547Google Scholar
  122. Versiani M, Cassano G, Perugi G et al (2002) Reboxetine, a Selective Norepinephrine Reuptake Inhibitor, is an effective and well-tolerated Treatment for Panic Disorder. J Clin Psychiatry 63(l):31–37CrossRefGoogle Scholar
  123. Wade AG, Lepola U, Koponen J, Pedersen V, Pedersen T (1997) The effect of citalopram in panic disorder. Br J of Psychiatry 170:549–553CrossRefGoogle Scholar
  124. Waldinger M, Hengeveld MW, Zwinderman AH et al (1998) Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 18(4):274–281PubMedCrossRefGoogle Scholar
  125. Weissman MM et al (1988) The epidemiology of dysthymia in five communities: rates, risks, comorbidity and treatment. Am J Psychiatry 145:815–819PubMedGoogle Scholar
  126. Wells K, Sherbourne C, Schoenbaum Met al (2000) Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA 283:212–230PubMedCrossRefGoogle Scholar
  127. Wheatley D (1998) Vergleich des Johanniskrautextraktes LI 160 mit Amitriptylin bei leichter bis mittelschwerer Depression. Psychopharmakother Suppl 8:8–11Google Scholar
  128. Wheeler Vega LA, Mortimer AM, Tyson PJ (2000) Somatic treatment of psychotic depression: review and recommendations for practice. J Clin Psychopharmacol 20:504–519Google Scholar
  129. Winkler D et al (2002) Maintenance treatment in depression: the role of pharmacological and psychological treatment. Curr Opin Psych 15(l):63–68CrossRefGoogle Scholar
  130. Wittchen HU (2000) Epidemiology of affective disorders. In: Helmchen H, Henn F, Lauter H, Sartorius (eds) Contemporary Psychiatry, Vol 3. Springer, HeidelbergGoogle Scholar
  131. World Federation of Societies of Biological Psychiatry (WFSBP) (2002) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder. J Biol Psychiatry 3(l):5–44. Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions 3(2):69-87Google Scholar
  132. Yonkers K, Gullion C, Williams A et al (1998) Paroxetine as a treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 16(l):3–8Google Scholar
  133. Zajecka JM (2000) Clinical Issues in Long-Term Treatment with Antidepressants. J Clin Psychiatry 61(suppl 2):20–25PubMedGoogle Scholar
  134. Zanardi R, Franchini L, Gasperini M et al (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153:1631–1633PubMedGoogle Scholar
  135. Zohar J, Judge Ret al (1996) Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Brit J Psychiatr 169:468–474CrossRefGoogle Scholar

Literatur zu Abschnitt 4.2

  1. Beckmann H, Haas S (1984) Therapie mit Benzodiazepinen: eine Bilanz. Nervenarzt 55:111–121PubMedGoogle Scholar
  2. Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. Berner P (1982) Psychiatrische Systematik. Huber, Bern Stuttgart WienGoogle Scholar
  4. Braestrup C, Nielsen M, Olsen CE (1980) Urinary and brain β-carboline-3-carbo-cylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci USA 77:2288–2292PubMedCrossRefGoogle Scholar
  5. Braestrup C, Schmiechen R, Neef G, Nielsen M, Petersen EN (1982) Interaction of convulsive ligands with benzodiazepine receptors. Science 216:1241–1243PubMedCrossRefGoogle Scholar
  6. Chase MH, Parmeggiani PL, O’Connor C (1991) Sleep research, vol 20 A. In: World Fed Sleep Res Soc, Found Congr, Cannes Fr, Sept 21-25, 1991Google Scholar
  7. Clarenbach P, Klotz U, Koella WP, Rudolf GAE (1991) Schering Lexikon der Schlafmedizin. Medizin, MünchenGoogle Scholar
  8. Cluydts R, Peeters K et al (1998) Comparison of Continous versus Intermittent Administration of Zolpidem in Chronic Insomniacs: a Double-blind, Randomized Pilot Study. J Int Med Res 26:13–24PubMedGoogle Scholar
  9. Costa E, Guidotti A, Mao CC (1975) New concepts on the mechanism of actions of benzodiazepines. Life Sci 17:167–186PubMedCrossRefGoogle Scholar
  10. Davidson JRT, DuPont RL, Hedges D, Haskins T (1999) Efficacy, Safety and Tolerability of Venlafaxine Extended Release and Buspirone in Outpatients with Generalized Anxiety Disorder. J Clin Psychiatry 60(8):528–535PubMedCrossRefGoogle Scholar
  11. Delle Chiaie R, Pancheri P, Casacchia M et al (1995) Assessment of the efficacy of buspirone in patients affected by generalised anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, doubleblind study. J Clin Psychopharmacol 15:12–19PubMedCrossRefGoogle Scholar
  12. Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C (1983) Severe anxiety induced by FG 7142, a β-carboline receptor. Lancet II:98–99CrossRefGoogle Scholar
  13. Freeman H, Puech AJ, Roth T (eds) (1996) Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Elsevier, ParisGoogle Scholar
  14. Friedberg KD, Rüfer R (1986) Benzodiazepine. Urban 8c Schwarzenberg, MünchenGoogle Scholar
  15. Gilin JC, Byerley WF (1990) The diagnosis and management of insomnia. N Engl J Med 322(4):239–247CrossRefGoogle Scholar
  16. Griffiths RR, Sannerud CA (1987) Abuse of and dependence on benzodiazepines and other anxiolytic/sedative drugs. In: Meltzer HY et al (1987) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1535–1541Google Scholar
  17. Griffiths RR, Summerud JD (1985) The benzodiazepines. In: Smith DE, Wesson DR (eds) Current standards for medical practice. MTP, Lancaster, pp 209–225CrossRefGoogle Scholar
  18. Griffiths RR, McLeod D, Bigelow GE, Liebson IA, Roach JD (1984) Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology 84:147–154PubMedCrossRefGoogle Scholar
  19. Haase HJ (1982) Therapie mit Psychopharmaka und anderen psychotropen Medikamenten. Schattauer, StuttgartGoogle Scholar
  20. Hindmarch I, Ott H, Roth T (1984) Sleep, benzodiazepines and performance. Psychopharmacology Suppl. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  21. Hippius H, Engel RR, Laakmann G (1986) Benzodiazepine. Rückblick und Ausblick. Springer, HeidelbergGoogle Scholar
  22. Hoey LL, Nahum A, Vance-Bryan K (1994) A retrospective review and assessment of benzodiazepines in the treatment of alcohol withdrawal in hospitalized patients. Pharmacotherapy 14(5):572–578PubMedGoogle Scholar
  23. Janke W, Netter P (1986) Angst und Psychopharmaka. Kohlhammer, StuttgartGoogle Scholar
  24. Kimbel KH (1984) Arzneimittel und Schlaflosigkeit: Stellungnahme einer amerikanischen Expertenkonferenz. 48(40):2892–2897Google Scholar
  25. Klotz U (1985) Tranquillantien. Therapeutischer Einsatz und Pharmakologie. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  26. Lader MH, Marks IM (1971) Clinical anxiety. Heinemann, LondonGoogle Scholar
  27. Lader MH (1994) Benzodiazepines: a Risk-Benefit Profile. CNS Drugs l(5):377–387CrossRefGoogle Scholar
  28. Langer G, Heimann H (1983) Psychopharmaka. Springer, WienCrossRefGoogle Scholar
  29. Laux G (1988) Psychopharmaka — ein Leitfaden. Fischer, Stuttgart New YorkGoogle Scholar
  30. Laux G (1989) Tranquilizer; Psychiatrie für den Praxisalltag. Hippokrates, StuttgartGoogle Scholar
  31. Linde OK (1988) Pharmakopsychiatrie im Wandel der Zeit. Tilia, Klingenmünster Monti J, Monti D (1995) Pharmacological treatment of chronic insomnia. CNS Drugs 4:182–194Google Scholar
  32. Müller C (1973) Lexikon der Psychiatrie. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  33. Müller-Oerlinghausen B (1984) Benzodiazepine — wo liegen die Gemeinsamkeiten, wo die Unterschiede. Psycho 10:561–573Google Scholar
  34. Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU (2002) Generalized anxiety disorder: comorbidity comparative biology and treatment. International Journal of Neuropsychopharmacology 5:315–325PubMedCrossRefGoogle Scholar
  35. Pöldinger W, Gander G (1979) Psychopharmaka in der Praxis. Roche, ParisGoogle Scholar
  36. Pollack MH (2002) Treatment of Anxiety Disorders in the Presence of Comorbid Depression. http://www.medscape.com/viewarticle/436974_3
  37. Rickels K, Case WG, Downing RW, Winokur A (1985) Benzodiazepine Use and Abuse. In: Hemali D, Racagni G (eds) Chronic treatments in neuropsychiatry. Raven, New York, pp 193–204Google Scholar
  38. Rüther E et al (1992) Epidemiologie, Pathophysiologie, Diagnostik und Therapie von Schlafstörungen. MHW 134, 8/29:460–466Google Scholar
  39. Saletu B (1989) Biologische Psychiatrie. Thieme, StuttgartGoogle Scholar
  40. Schmidt LG (1988) Zur Häufigkeit primärer Benzodiazepinabhängigkeit, A-2598 (56). Dtsch Ärztebl 85:38Google Scholar
  41. Schmidt RF, Vogel ME, Zimmermann M (1967) Die Wirkung von Diazepam auf die präsynaptische Hemmung und andere Rückenmarksreflexe. Arch Pharmakol Exp Pathol 258:69–82CrossRefGoogle Scholar
  42. Schofield PR, Darlison MG, Jujiita N, Burt DR, Stephenson FA, Rodriguez H, Rhel LM, Ramachandran I, Reale V, Glencorse TA, Seeburg PH, Barnard EA (1987) Sequence and functional expression of the GABA-A receptor shows a ligandgated receptor super-family. Nature (London) 328:221–227PubMedCrossRefGoogle Scholar
  43. Sheehan DV (1982) Panic attacks and phobias. J Med 307:156–158Google Scholar
  44. Sheehan DV (1983) The anxiety disease. Bantam, New YorkGoogle Scholar
  45. Spector R, Rogers H, Roy D (1984) Psychiatry: common drug treatments; practical problems in medicine. Dunitz, LondonGoogle Scholar
  46. Sternbach L (1988) Die Benzodiazepinstory. In: Linde OK (Hrsg) Pharmakopsychiatrie im Wandel der Zeit. Tilia, Klingenmünster, S 271–299Google Scholar
  47. Young A, Klapp R, Sherbourne C, Wells K (2001) The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 58:55–61PubMedCrossRefGoogle Scholar
  48. Wang P, Berglund P, Kessler R (2000) Recent care of common mental disorders in the United States: prevalence and conformance with evidence based recommendations. J Gen Intern Med 15:284–292PubMedCrossRefGoogle Scholar
  49. Wiegand M, Berger B (1987) Welche Bedeutung haben Antidepressiva in der Behandlung von chronischen Schlafstörungen. In: Hippius H, Rüther E (Hrsg) Antidepressiva und Depressionsbehandlung in der ärztlichen Praxis. Springer, Berlin Heidelberg New York, S 52–59CrossRefGoogle Scholar
  50. Wildmann J, Möhler H, Vetter W, Ranalder V, Schmidt K, Maurer K (1987 a) Diazepam and N-desmethyldiazepam are found in rat brain and adrenal and may be of plant origin. J Neural Transmiss 70:383–398CrossRefGoogle Scholar

Literatur zu Abschnitt 4.3

  1. Ackenheil M, Hippius H, Matussek N (1978) Ergebnisse der biochemischen Forschung auf dem Schizophrenie-Gebiet. Nervenarzt 49:634–649PubMedGoogle Scholar
  2. Amsler HA, Teerenhovi I, Barth E et al (1977) Agranulocytosis in patients treated with Clozapine. A study of the Finnish epidemic. Acta Psychiat Scand 56:241–248PubMedCrossRefGoogle Scholar
  3. Andreasen NC (1987) The concept of negative symptoms: definition, specificity and significance. Psychiat Psychobiol II, 4:240–251Google Scholar
  4. Angst J, Bente D, Berner P et al (1971) Das klinische Wirkungsbild von Clozapin (Untersuchungen mit dem AMP-System). Pharmakopsychiat Neuropsychopharmakol 4:201–211CrossRefGoogle Scholar
  5. Arvanitis LA (1996) Clinical Profile of Seroquel™ (Quetiapine): An overview of recent clinical studies. In: Holliday SG, Ancill RJ, MacEwan GW (eds) Schizophrenia: Breaking down the barriers. John Wiley & Sons LtdGoogle Scholar
  6. Arvanitis LA, Miller BG (1996) ICI 204, 636, an atypical antipsychotic: Results from a multiple fixed-dose, placebo-controlled trial. Psychopharm Bulletin 32(3):391Google Scholar
  7. Ayd FJ Jr (1978) Haloperidol: twenty years’ clinical experience. J Clin Psychol 39b:807–814Google Scholar
  8. Ban TA, Ceskova E (1980) Long-acting antipsychotic drugs. Psychopharmacol 16:6–13Google Scholar
  9. Bauer D, Gärtner HJ (1983) Wirkungen der Neuroleptika auf die Leberfunktion, das blutbildende System, den Blutdruck und die Temperaturregulation. Pharmakopsychiatrie 16:23–29CrossRefGoogle Scholar
  10. Berzewski H (1983) Der psychiatrische Notfall. Perimed, ErlangenGoogle Scholar
  11. Bilder RM, Goldman RS, Volavka J et al (2002) Neurocognitive effects of clozapine, olanzapine, resperidone and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:18–1028CrossRefGoogle Scholar
  12. Bobon J, Pinchard A, Collard J (1972) Clinical classification of neuroleptic with special reference to their antimanic, antiautistic and ataraxic properties. Compr Psychiat 13:123–131PubMedCrossRefGoogle Scholar
  13. Borenstein P, Boyer P, Braconnier A et al (1989) Amisulpride. Expansion Scientifique Francaise, ParisGoogle Scholar
  14. Breier A (1995) The management of treatment-resistant schizophrenia. Current Opinion in Psychiatry 8(l):41–44CrossRefGoogle Scholar
  15. Brown GW, Birley JTL, Wing JK (1972) Influence of family life on the course of schizophrenic disorders: a replication. Br J Psychiat 121:241–258CrossRefGoogle Scholar
  16. Buchanan R, Koro CE, Weiss S, L’Italian GJ, Magder LS, Fedder DO (2002) Effect of Olanzapine and Risperidone use on Diabetes Risk in Schizophrenia. Int J Neuropsychopharm 5(suppl 1):169Google Scholar
  17. Bürki HR (1983) Neurobiochemische Wirkungen der Neuroleptika. In: Langer G, Heimann H (Hrsg) Psychopharmaka: Grundlagen und Therapie. Springer, Berlin Heidelberg New York, S 207–223Google Scholar
  18. Carlsson A (1978) Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiat 135(2):164–173Google Scholar
  19. Carlsson A (1990) In: Acad Prof Inf Serv NY (ed) Psychiatric topics 2(1)Google Scholar
  20. Carlsson A, Waters N, Waters S, Carlsson M (2000) Network Interactions in Schizophrenia — therapeutic implications. Brain Research Reviews 31:342–349PubMedCrossRefGoogle Scholar
  21. Casey DE (1996) “Seroquel”(Quetiapine). Preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5(8):939–957CrossRefGoogle Scholar
  22. Chong SA, Mahendran R (2001) Cardiac Effects of Psychotropic Drugs. Annals Academy of Medicine 30(6):625–631Google Scholar
  23. Copolov DL, Link CGG, Kowalcyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636,“Seroquel”) and haloperidol in schizophrenia. Psychological Medicine 30:95–105PubMedCrossRefGoogle Scholar
  24. Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X, Green M (2002) Neurocognitive Effects of Aripiprazolane versus Olanzapine in stable Psychosis. Int J Neuropsychopharmacol 5(suppl 1):185Google Scholar
  25. Costentin J (1987) Neuroleptiques et récepteurs dopaminergiques. Psychol Med 19, 13:2413–2416Google Scholar
  26. Crow TJ (1985) The two syndrom concept: origins and current status. Schizophr Bull II, 3:471–486Google Scholar
  27. Cuesta MJ, Peralta V, Zarzuela A (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophren Res 48:17–28CrossRefGoogle Scholar
  28. Daniel DG, Zimbroff DL, Potkin SG et al (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of Schizophrenia and Schizoaffective Disorder: A 6 Week Placebo Controlled Trial. Neuropsychopharmacology 20(5): 491–505PubMedCrossRefGoogle Scholar
  29. Davis JM (1976) Recent developments in the drug treatment of schizophrenia. Am J Psychiat 133:208–214PubMedGoogle Scholar
  30. Davis JM, Andriukaitis S (1986) The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 6:2 S–10 SCrossRefGoogle Scholar
  31. Davy JP (1987) Les neuroleptiques àaction prolongée. Psychol Med 19, 13: 2407–2410Google Scholar
  32. Delay J, Deniker P (1952) Trente-huit cas de psychoses traitées par la cure prolongée et continue de 4560 RP. In: 50 Congr Aliénistes et neurologues de la longue francaise, Luxembourg, 1952. Masson, ParisGoogle Scholar
  33. Delay J, Deniker P (1961) Méthodes chimothérapeutiques en psychiatrie. Masson, Paris, p 496Google Scholar
  34. Deniker P, Ginestet D (1973) Neuroleptiques. Encycl Med Chir Psychiat 37860b 20/2, 1–16 (Paris)Google Scholar
  35. Falloon IRH (1982) Family management in the prevention of exacerbations of schizophrenia. A controlled study. N Engl J Med 306:1437–1440PubMedCrossRefGoogle Scholar
  36. Faurbye A, Rasch PJ, Petersen PB et al (1964) Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiat Scand 40:10–27PubMedCrossRefGoogle Scholar
  37. Ferrari HA, Stephen CR (1966) Neuroleptanalgesia: pharmacology and clinical experiences with droperidol and fentanyl. S Afr Med J 59:815–820Google Scholar
  38. Gicklhorn R (1960) Ein Beitrag zur Geschichte der Rauwolfia. Med Welt 11: 1788–1792Google Scholar
  39. Goldstein MJ (1978) Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiat 35:1169–1177PubMedCrossRefGoogle Scholar
  40. Goren JL, Levin GM (1998) Quetiapine, an Atypical Antipsychotic. Pharmacotherapy 18(6):1183–1194PubMedGoogle Scholar
  41. Green MF, Braff DL (2001) Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 49:374–384PubMedCrossRefGoogle Scholar
  42. Haase HJ (1961) Das therapeutische Achsensyndrom neuroleptischer Medikamente und seine Beziehungen zur extrapyramidalen Symptomatik. Fortschr Neurol Psychiat 29:245–268PubMedGoogle Scholar
  43. Haase HJ (1976) Therapie mit Psychopharmaka und anderen seelischen Befinden beeinflussenden Medikamenten, 4. Aufl. Schattauer, StuttgartGoogle Scholar
  44. Haase HJ: Dosierung der Neuroleptica. Schwerpunktmedizin 5, 2 (Sonderh)Google Scholar
  45. Hamner MB, Arvanitis LA, Miller B G et al (1996) Plasma Prolactin in Schizophrenia Subjects Treated with “Seroquel”(ICI 204, 636). Psychopharmacol Bulletin, 32(l):107–110Google Scholar
  46. Hirsch SR, Gaind R, Rohde PD et al (1973) Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Br Med J I:633–637CrossRefGoogle Scholar
  47. Hirsch SR, Link CG, Goldstein JM, Arvanitis LA (1996) ICI 204, 636: a new Atypical Antipsychotic Drug. Brit J Psychiatry 168(suppl 29):45–56Google Scholar
  48. Hogarty GE (1984) Depot neuroleptics: the relevance of psychosocial factors — a United States perspective. J Clin Psychiat 45(5, Sec 2):36–42Google Scholar
  49. Hong WW, Arvanitis LA (1996) Reduction of the positive symptoms of schizophrenia by “Seroquel”(ICI 204, 636): Results from phase II and III clinical trials. Europ Neuropsychopharm 6(suppl 4):S 4–125Google Scholar
  50. Hyman SE (ed) (1984) The suicidal patient. In: Manual of psychiatric emergencies. Little, Brown, Boston TorontoGoogle Scholar
  51. Inoue Y (1991) Mitteilung an den 17. Kongress des International College of Neuropsychopharmacology. In: Acad Prof Inf Serv NY (ed) Psychiatric topics, (3)1Google Scholar
  52. Janssen PAJ, Van Bever WFM (1975) Advances in the search for improved neuroleptic drugs. Curr Dev Psychopharmacol 2:167Google Scholar
  53. Janssen PAJ, Tollenaere JP (1982) Pimozide. In: Bindra JS, Lednicer D (eds) Chronicles of drug discovery, vol 2. John Wiley & Sons, New York, pp 33–47Google Scholar
  54. Janssen PAJ, Niemegeers CJE, Awouters F et al (1988) Pharmacology of risperidone (R 64766) a new antipsychotic with serotonin-S2 and Dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693PubMedGoogle Scholar
  55. Kähler HJ (1970) Rauwolfia Alkaloide. Boehringer, MannheimGoogle Scholar
  56. Kane JM, Rifkin A, Woerner M et al (1985) High-dose versus low-dose strategies in the treatment of schizophrenia. Psychpharmacol Bull 21, 3:533–537Google Scholar
  57. Kane JM, Carson WH, Saha AR et al (2002) Efficacy and Safety of Aripiprazole and Haloperidol versus Placebo in Patients with Schizophrenia and Schizoaffective Disorder. J Clin Psychiatry 63(9):763–771PubMedCrossRefGoogle Scholar
  58. Kapsmabelis V, Gekiere CI, Ginestet D (1990 a) Classifications cliniques des neuroleptiques — étude critique et perspectives actuelles. Encephale 14:63–70Google Scholar
  59. Kapsmabelis V, Serra P, Ginestet D (1990 b) Le syndrome déficitaire: historique, séneiologie et quelques réflexions. Nerv Psychiat 3 (Spec No Jan 1990)Google Scholar
  60. Keck P, Buffenstein A, Ferguson J et al (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 week placebo controlled trial. Psychopharmacology 140:173–184PubMedCrossRefGoogle Scholar
  61. Kline NS (1954) Use of rauwolfia in neuropsychiatric conditions. Ann NY Acad Sci 59:107PubMedCrossRefGoogle Scholar
  62. Koro CE, Fedder DO, L’Italiana GJ et al (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 50:1021–1026CrossRefGoogle Scholar
  63. Kupfer DJ, Sartorius N (eds) (2002) The Usefulness and Use of Second-Generation Antipsychotic Medications. Supplement to Current Opinion in Psychiatry, vol 15, suppl 1, March 2002Google Scholar
  64. Laborit H (1951) L’anesthésie facilitée par les synergies médicamenteuses. Masson, ParisGoogle Scholar
  65. Lambert PA, Revol L (1960) Classification psychopharmacologique et Unique des différents neuroleptiques. Indications thérapeutiques générales dans les psychoses. Presse Med 41:1509–1511Google Scholar
  66. Lecrubier Y (1987) Doit-on envisager une classification des neuroleptiques tenant mieux compte des mécanismses d’action et des différents syndromes-cibles? Psychiat Psychobiol 2:232–238Google Scholar
  67. Leff JP, Knipers L, Berkowitz R (1982) A controlled trial of social intervention in the families of schizophrenic patients. Br J Psychiat 141:121–134CrossRefGoogle Scholar
  68. Lenert LA, Ziegler J, Lee T (2000) Differences in health values among patients, family members and providers of outcome in schizophrenia. Med Care 10:1011–1021CrossRefGoogle Scholar
  69. Lindström L, Wieseigren IM, Akselson S et al (1990) Mitteilung an das Osloer Regionalsymposium der WPA. In: Acad Prof Inf Serv NY (ed) Psychiatrie topica (3)1Google Scholar
  70. Martin S, Loo H, Peuskens J, Thirumalai Set al (2002) A Double-blind, Randomized Comparative Trial of Amisulpride versus Olanzapine in the Treatment of Schizophrenia: Short-term Results at Two Months. Current Medical Research and Opinians 18(6):355–362CrossRefGoogle Scholar
  71. May PRA, Tuma AH, Dixon WJ (1976 a) Schizophrenia — a follow-up study of results of treatment. I. Design and other problems. Arch Gen Pschiat 33:474–478CrossRefGoogle Scholar
  72. May PRA, Tuma AH, Yale C et al (1976 b) Schizophrenia — a follow-up study of results of treatment. II. Hospital stay over two to five years. Arch Gen Psychiat 33:481–486PubMedCrossRefGoogle Scholar
  73. Meltzer HY (2001) Treatment of suicidality in schizophrenia. Ann NY Acad Sci 932:44–58PubMedCrossRefGoogle Scholar
  74. Moldavsky M, Stein D, Benatov R et al (1998) Combined clozapine-lithium treatment for schizophrenia and schizoaffective disorder. Eur Psychiatry13:104–106PubMedCrossRefGoogle Scholar
  75. Müller P, Kind J, Lohrengel S et al (1977) Die neuroleptische Rezidivprophylaxe schizophrener Psychosen. Vorläufige Mitteilung. Nervenarzt 48:560–561Google Scholar
  76. Mullen J, Jibson MD, Sweitzer D (2001) A Comparison of the Relative Safety, Efficacy and Tolerability of Quetiapine and Risperidone in Outpatients with Schizophrenia and other Psychotic Disorders: The Quetiapine Experience with Safety and Tolerability (QUEST) Study. Clinical Therapeutics 23(11):1839–1854PubMedCrossRefGoogle Scholar
  77. Naber D, Moritz S, Lambert M et al (2001) Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79–88PubMedCrossRefGoogle Scholar
  78. Nasrallah HA, Duchesne I, Mehnert A, Janagap C (2002) Long acting risperidone injection improves quality of life. XXIII CINP, Montreal CanadaGoogle Scholar
  79. Niemeggers CJE, Awouters F, Janssen PAJ (1990) Antagonisme de la sérotonine impliqué dans l’éffet antipsychotique — confirmations par la ritansérine et le risperidone. Encephale 16:147–151Google Scholar
  80. Oegren SO, Hall H, Koehler C et al (1983) Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474CrossRefGoogle Scholar
  81. Petit M, Colonna L (1978) Critères de choix d’un neuroleptique. Entretiens de Bichat. Thérapeutique expansion scientifique francaise, Paris, pp 306–308Google Scholar
  82. Rondot P, Bathien N (1979) Mouvements anormaux induits par les médicaments psychotropes. Encephale 5:41–48PubMedGoogle Scholar
  83. Rouillon F (1988) Effects extrapyramidaux des neuroleptiques et leurs traitements. Synapse 43:81–88Google Scholar
  84. Schneider W (1955) Die Erforschung der Rau wolf-Alkaloide von ihren Anfängen bis zur Gegenwart. Arzneimittelforschung (Drug Res) 5:666–672Google Scholar
  85. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y (2002) Amisulpiride vs Risperidone in Chronic Schizophrenia: Results of a 6-month Double-blind Study. Neuropsychopharm 27(6):1071–1081CrossRefGoogle Scholar
  86. Seeman M, Seeman P (2002) Choosing an Antipsychotic and Why.http://www.medscape.com/viewprogram/2013_pnt and 2014_pnt
  87. Simon P, Lecrubier Y, Puech AJ (1984) Classification des neuroleptiques. Rev Pract 34, 13:589–594Google Scholar
  88. Sowell MO, Mukhopadhyay N, Cavazzoni P et al (2002) Hyperglygemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo. J Clin End Metab 87(6):2918–2923CrossRefGoogle Scholar
  89. Stevens BC (1973) Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community. Psychol Med 3:141–158PubMedCrossRefGoogle Scholar
  90. Task Force on late Neurological Effects of Antipsychotic Drugs (ed) (1980) Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiat 137:1163–1172Google Scholar
  91. Tölle R (1986) Malignes neuroleptisches Syndrom. Dtsch Ärztebl 83:3102–3103Google Scholar
  92. Vaughn CE, Leff J (1976) The influence of family and social factors on the course of psychiatric illness. A comparison of schizophrenic and depressed neurotic patients. Br J Psychiat 129:125–137CrossRefGoogle Scholar
  93. Vaughn CE, Sorensen Snyder K, Jones S (1984) Family factors in schizophrenic relapse. Arch Gen Psychiat 41:1169–1177PubMedCrossRefGoogle Scholar
  94. Volavka J, Czabor P, Sheitman B et al (2002) Clozapine, Olanzapine, Risperidone and Haloperidol in the Treatment of Patients with Chronic Schizophrenia and Schizoaffective Disorder. Am J Psychiatry 159:255–262PubMedCrossRefGoogle Scholar
  95. Voruganti L, Cortese L, Oyewumi L et al (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr Res 43:135–145PubMedCrossRefGoogle Scholar
  96. Wadworth AN, Heel RC (1990) Remoxipride — a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 40(6):863–879PubMedCrossRefGoogle Scholar
  97. Weitbrecht HJ (1972) Depressive und manisch-depressive Psychosen. In: Kisker KP, Meyer JE, Müller M, Strögren E (Hrsg) Psychiatrie der Gegenwart, Bd. II 1, 2. Aufl. Springer, Berlin Heidelberg New YorkGoogle Scholar
  98. Welch R, Chue P (2000) Antipsychotic agents and QT changes. J Psychiatry Neuroscience 25(2):154–160Google Scholar
  99. WHO (ed) (1973) The international pilot study of schizophrenia, vol 1. WHO, GenevaGoogle Scholar
  100. Woggon B (1979) Neuroleptikaabsetzversuche bei chronisch schizophrenen Patienten. I. Literaturzusammenfassung. Int Pharmacopsychiat 14:34Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Margot Schmitz
    • 1
    • 2
  1. 1.WienAustria
  2. 2.WienAustria

Personalised recommendations